A scientifically proven alternative to the Zinc Oxide and enteric antibiotics
SILO as first company in the world developed, patented and launched on the market 1-Mono-glycerides of short and medium chain fatty acids to be used in animal nutrition.
SILO has been developing the technical know-how on the efficacy of 1- Mono-glycerides and on their applications for over 10 years.
The attempts at imitation of SILO products are really numerous, but without the expected success!
SILOhealth Swine is a synergistic combination of short and medium chain 1-Monoglycerides.
The efficacy of SILOhealth Swine as alternative to enteric antibiotics and to the ZnO has been validated in a very large experimental program and is confirmed in our everyday field experience.
- ECan be used in combination with the standard antibiotic programs of the farm or in replacement of enteric antibiotics and ZnO
- ESupports gut health in presence of E. coli, hemolytic E. coli, Clostridium perfringens, Salmonella spp.
- EStrongly increases the survival rate
- EImproves the gut integrity in presence of coccidiosis
- EDown-regulates myostatin, increases muscle mass (meat yield)
- ENo negative effects on Lactobacillus
- EImproves litters quality, FCR
- EStrongly improves survival rate
- EAvailable in dry and liquid form, for feed and drinking water applications
- ENon corrosive
- ENeutral taste and odor
- EPackaging: 25 kg bag, big bags, 20 kg cans, 1000 kg IBC
- EHeat stable up to 200 ° C
- ECompatible with all ingredients of feed and premixes
- EProduced in GMP+ / ISO / QS / FamiQS certified facilities
Quarantelli, A. 2019. 1-Monoglycerides of short and medium chain fatty acids reduced pathogenic intestinal bacteria, post-weaning diarrhoea, mortality and myostatin level in piglets – Engormix
Parini, M. 2020. 1-Mоноглицериды: эффективная замена антибиотиков (1-Monoglycerides: effective replacement of antibiotics) – Комбикорма (Compound Feeds)
Data from the study published in 2019, A. Quarantelli, Engormix
Number of Piglets: 180
The antibiotic group received a commercial feed supplemented with Doxycycline during the first 40 days and with Sulfadiazine and Trimethoprim during the subsequent 30 days of the trial.
The SILOhealth group received the same commercial diet supplemented with 4kg of SILOhealth/ton of feed during the first week and with 3kg of SILOhealth/ton of feed during the subsequent 63 days of the trial.
Performance from 0 to 70 days
The SILOhealthgroup showed improved ADG, FCR, diarrhea score and survival rate compared to the antibiotic group. Furthermore, the microbiological analysis of faeces samples showed a significantly lower content of pathogenic bacteria in the SILOhealth group compared to the antibiotics group.